Literature DB >> 3930442

Increased radiosensitivity of tumors by perfluorochemicals and carbogen.

C W Song, W L Zhang, D M Pence, I Lee, S H Levitt.   

Abstract

The efficacy of an emulsion of perfluorochemicals (Fluosol-DA) to sensitize RIF-1 tumors of C3H mice to radiation was studied. An i.v. injection of 12 ml/kg of Fluosol-DA (20%) to tumor-bearing animals and keeping the animals in an atmosphere of a mixture of O2 (95%) and CO2 (5%) (carbogen) for 1 hr before and during irradiation of s.c. tumors in the thigh significantly enhanced the tumoricidal effect of radiation as measured with growth delay of the treated tumors. A lesser but significant enhancement of radiation damage in the tumors was also observed when the animals were kept in carbogen for 1 hr without injection of Fluosol-DA. It was concluded that Fluosol-DA increased the delivery of oxygen to hypoxic areas in the tumors and enhanced the response of hypoxic cells to radiation.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3930442     DOI: 10.1016/0360-3016(85)90041-0

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  4 in total

1.  The influence of Fluosol-DA and carbogen breathing on the antitumor effects of cyclophosphamide in vivo.

Authors:  G E Kim; C W Song
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

Review 2.  Hypoxia and drug resistance.

Authors:  B A Teicher
Journal:  Cancer Metastasis Rev       Date:  1994-06       Impact factor: 9.264

3.  Further evaluation of nicotinamide and carbogen as a strategy to reoxygenate hypoxic cells in vivo: importance of nicotinamide dose and pre-irradiation breathing time.

Authors:  D J Chaplin; M R Horsman; D W Siemann
Journal:  Br J Cancer       Date:  1993-08       Impact factor: 7.640

4.  Nicotinamide, Fluosol DA and Carbogen: a strategy to reoxygenate acutely and chronically hypoxic cells in vivo.

Authors:  D J Chaplin; M R Horsman; D S Aoki
Journal:  Br J Cancer       Date:  1991-01       Impact factor: 7.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.